On May 12, 2025, Truist Securities analyst David Macdonald maintained his 'Buy' rating on CVS Health (CVS, Financial). The analyst has also raised the price target for the stock from the previous target of USD 82.00 to a new target of USD 84.00. This adjustment represents a 2.44% increase in the price target.
The decision to maintain the 'Buy' rating and adjust the price target reflects the analyst's continued positive sentiment towards CVS Health's (CVS, Financial) future performance in the stock market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CVS Health Corp (CVS, Financial) is $78.22 with a high estimate of $95.00 and a low estimate of $70.00. The average target implies an upside of 22.77% from the current price of $63.71. More detailed estimate data can be found on the CVS Health Corp (CVS) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, CVS Health Corp's (CVS, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CVS Health Corp (CVS, Financial) in one year is $84.98, suggesting a upside of 33.39% from the current price of $63.71. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CVS Health Corp (CVS) Summary page.
